CFD Guided Optimization of Nose-to-Lung Aerosol Delivery in Adults: Effects of Inhalation Waveforms and Synchronized Aerosol Delivery.
high flow nasal cannula
high-efficiency aerosol delivery
nebulized aerosol
pharmaceutical aerosols
trans-nasal aerosol delivery
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
24 Sep 2020
24 Sep 2020
Historique:
received:
06
05
2020
accepted:
01
09
2020
entrez:
24
9
2020
pubmed:
25
9
2020
medline:
29
6
2021
Statut:
epublish
Résumé
The objective of this study was to optimize nose-to-lung aerosol delivery in an adult upper airway model using computational fluid dynamics (CFD) simulations in order to guide subsequent human subject aerosol delivery experiments. A CFD model was developed that included a new high-flow nasal cannula (HFNC) and pharmaceutical aerosol delivery unit, nasal cannula interface, and adult upper airway geometry. Aerosol deposition predictions in the system were validated with existing and new experimental results. The validated CFD model was then used to explore aerosol delivery parameters related to synchronizing aerosol generation with inhalation and inhalation flow rate. The low volume of the new HFNC unit minimized aerosol transit time (0.2 s) and aerosol bolus spread (0.1 s) enabling effective synchronization of aerosol generation with inhalation. For aerosol delivery correctly synchronized with inhalation, a small particle excipient-enhanced growth delivery strategy reduced nasal cannula and nasal depositional losses each by an order of magnitude and enabled ~80% of the nebulized dose to reach the lungs. Surprisingly, nasal deposition was not sensitive to inhalation flow rate due to use of a nasal cannula interface with co-flow inhaled air and the small initial particle size. The combination of correct aerosol synchronization and small particle size enabled high efficiency nose-to-lung aerosol delivery in adults, which was not sensitive to inhalation flow rate.
Identifiants
pubmed: 32968848
doi: 10.1007/s11095-020-02923-8
pii: 10.1007/s11095-020-02923-8
pmc: PMC8663055
mid: NIHMS1759232
doi:
Substances chimiques
Aerosols
0
Bronchodilator Agents
0
Nasal Sprays
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL107333
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL107333
Pays : United States
Références
J Aerosol Med Pulm Drug Deliv. 2011 Apr;24(2):103-18
pubmed: 21410327
Curr Med Chem. 2013;20(12):1531-40
pubmed: 22963554
J Biomech Eng. 2013 Sep;135(9):91010
pubmed: 23722698
J Aerosol Med Pulm Drug Deliv. 2018 Aug;31(4):248-254
pubmed: 29261402
J Intensive Care. 2015 Mar 31;3(1):15
pubmed: 25866645
Pharm Res. 2013 Nov;30(11):2917-30
pubmed: 23801087
Inhal Toxicol. 2006 Sep;18(10):795-801
pubmed: 16774869
Eur J Pharm Sci. 2013 Jun 14;49(3):390-9
pubmed: 23608613
Respir Care. 2017 Sep;62(9):1186-1192
pubmed: 28588117
Pharm Res. 1997 Mar;14(3):354-7
pubmed: 9098880
Respir Care. 2009 May;54(5):658-70
pubmed: 19393109
Respir Med. 2006 Apr;100(4):721-8
pubmed: 16139491
Respir Care. 2015 Jun;60(6):894-914; discussion 914-6
pubmed: 26070582
Aerosol Sci Technol. 2011 Jan 1;45(7):884-899
pubmed: 21804683
Int J Pharm. 2018 Jul 30;546(1-2):1-9
pubmed: 29733972
Respir Care. 2013 Jan;58(1):98-122
pubmed: 23271822
Respir Care Clin N Am. 2001 Jun;7(2):175-213, v
pubmed: 11517020
J Aerosol Med. 2007;20 Suppl 1:S85-98; discussion S98-9
pubmed: 17411410
J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):145-56
pubmed: 23025452
J Aerosol Med. 2006 Winter;19(4):473-83
pubmed: 17196076
Respir Med. 2009 Oct;103(10):1400-5
pubmed: 19467849
J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):248-65
pubmed: 23286828
Respir Care. 2015 Jun;60(6):806-21; discussion 821-4
pubmed: 26070576
J Aerosol Sci. 2014 Dec 1;78:11-29
pubmed: 25308992
Expert Opin Drug Deliv. 2004 Nov;1(1):165-76
pubmed: 16296727
Pharm Res. 2010 Sep;27(9):1800-11
pubmed: 20454837
J Aerosol Med. 2006 Spring;19(1):61-6
pubmed: 16551216
Ann Biomed Eng. 2012 Dec;40(12):2596-610
pubmed: 22820981
J Aerosol Med Pulm Drug Deliv. 2008 Jun;21(2):181-8
pubmed: 18518794
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):134-41
pubmed: 26196740
Ann Biomed Eng. 2013 Jun;41(6):1217-32
pubmed: 23423706
Aerosol Sci Technol. 2003;37(8):659-671
pubmed: 19011693
Adv Drug Deliv Rev. 2015 May;85:24-43
pubmed: 25193067
Pulm Ther. 2019 Jun;5(1):43-54
pubmed: 32026423
Pediatr Crit Care Med. 2013 Jun;14(5):e250-6
pubmed: 23628834
Aerosol Sci Technol. 2014;48(4):434-449
pubmed: 24932058
Curr Opin Pulm Med. 2009 Jan;15(1):19-24
pubmed: 19077701
J Aerosol Sci. 2018 May;119:31-50
pubmed: 30349146
J Aerosol Med Pulm Drug Deliv. 2012 Apr;25(2):63-78
pubmed: 22191396
J Appl Physiol. 1971 Aug;31(2):207-17
pubmed: 5558242
J Aerosol Med Pulm Drug Deliv. 2017 Oct;30(5):349-358
pubmed: 28463044
Pulm Ther. 2018 Jun;4(1):73-86
pubmed: 32026245
Curr Opin Crit Care. 2007 Feb;13(1):27-38
pubmed: 17198046
J Aerosol Med Pulm Drug Deliv. 2012 Dec;25(6):319-32
pubmed: 22856594
Respir Care. 2011 Sep;56(9):1411-21; discussion 1421-3
pubmed: 21944688
J Aerosol Med Pulm Drug Deliv. 2017 Jun;30(3):190-205
pubmed: 28075194
J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):266-79
pubmed: 23273243
J Aerosol Med Pulm Drug Deliv. 2015 Jun;28(3):189-201
pubmed: 25192072
J Aerosol Med Pulm Drug Deliv. 2019 Aug;32(4):224-241
pubmed: 30855199
Respir Care. 2015 Jun;60(6):880-91; discussion 891-3
pubmed: 26070581
Pharm Res. 2012 Mar;29(3):707-21
pubmed: 21948458
Nat Rev Drug Discov. 2013 Jul;12(7):543-59
pubmed: 23977698
Respir Care. 2014 Oct;59(10):1476-86
pubmed: 24917454
J Pharm Pharmacol. 2012 Sep;64(9):1254-63
pubmed: 22881438
J Cyst Fibros. 2013 Sep;12 Suppl 2:S1-20
pubmed: 24064077
J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):223-229
pubmed: 28157412